Thank you!
Your email has been successfully added to our mailing list.
CLOSE
Home
Blog
Resources
Why News Quantified Works
The Ultimate Earnings Guide
STOCK MARKET 101
About Us
Contact
Services
Institutions
Sign up
Log in
Home
Blog
Resources
Why News Quantified Works
The Ultimate Earnings Guide
STOCK MARKET 101
About Us
Contact
Services
Institutions
Log in
Sign up
×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
No thanks
Home
URGN
News
URGN –
urogen pharma ltd
(US:NASDAQ)
DELAYED
<
$
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
——
URGN
SPY
QQQ
SPX
News
Earning News
Analyst Actions
SEC Filings
Date
Time
Symbol
Headline
Impact
11/17
08:00 am
urgn
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low
REPORT
11/11
08:00 am
urgn
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
Low
REPORT
11/10
12:41 pm
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN
) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $48.00 to $40.00.
Low
REPORT
11/10
08:00 am
urgn
UroGen Pharma Announces November 2020 Conference Schedule
Medium
REPORT
11/9
07:07 pm
urgn
UroGen Pharma Ltd. (URGN) Q3 2020 Earnings Call Transcript [The Motley Fool]
Medium
REPORT
11/9
08:00 am
urgn
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
Medium
REPORT
11/2
08:00 am
urgn
UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020
Low
REPORT
10/30
12:10 am
urgn
Urogen Pharma Ltd (NASDAQ: URGN) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
Low
REPORT
10/8
04:12 am
urgn
Urogen Pharma Ltd (NASDAQ: URGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
Low
REPORT
10/5
08:00 am
urgn
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
REPORT
9/26
02:05 am
urgn
Urogen Pharma Ltd (NASDAQ: URGN) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
Low
REPORT
9/21
01:08 pm
urgn
Urogen Pharma Ltd (NASDAQ: URGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $26.00.
Low
REPORT
9/10
08:00 am
urgn
UroGen Pharma Announces September 2020 Conference Schedule
Low
REPORT
9/9
08:00 am
urgn
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
Medium
REPORT
9/8
07:38 am
urgn
Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Medium
REPORT
9/4
08:00 am
urgn
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
REPORT
Live Event:
Click Here To Register For The Live Online Workshop
Latest Posts
Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day